NCT04607772 2025-10-03Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)Karyopharm Therapeutics IncPhase 1/2 Withdrawn
NCT04882163 2021-10-05Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaCelgenePhase 1/2 Withdrawn